Receive our newsletter – data, insights and analysis delivered to you
  1. Research Reports
January 19, 2017

Report: Lupus market to reach $3.2bn in value by 2025

The launch of new first-in-class products is expected to drive growth in the lupus market at a compound annual growth rate of 10.6%, according to a report by GlobalData.

The launch of new first-in-class products is expected to drive growth in the lupus market at a compound annual growth rate of 10.6%, according to a report by GlobalData.

Titled ‘PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis – Global Drug Forecast and Market Analysis to 2025’, the report covers the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan.

Including systemic lupus erythematosus (SLE) and lupus nephritis (LN), the lupus market is expected to be driven by the launch first-in-class pipeline drugs anifrolumab, Orencia (abatacept), and Lupuzor, as well as therapeutic drugs, atacicept, blisibimod, and voclosporin.

AstraZeneca’s anifrolumab is an anti-interferon monoclonal antibody (mAb) expected to dominate the lupus market with demonstrated efficacy in patients with cutaneous and articular involvement. The drug is expected to acquire a 75% share of all SLE patients and also drive the development of other anti-interferon mAbs.

"The report also projects the increase in prevalence of lupus across the 7MM and better awareness of the disease to result in the rise in uptake of lupus medications."

The report also projects the increase in prevalence of lupus across the 7MM and better awareness of the disease to result in the rise in uptake of lupus medications.

GlobalData healthcare analyst Sebastian S. Gehrke states that anti-malarials, steroids, and other immunosuppressive agents will continue to dominate the market. Gehrke also anticipates biologics to witness an increase in uptake and strengthen their dominance in the market.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

A large share of patients still lack access to efficient medication despite the launch of new pipeline drugs. The existing medications available in the market possess undesirable safety profiles. In addition, poor understanding of the etiology of lupus has resulted in a high unmet need of patients.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU